Want to see XLO full AI Analyst Report?

Xilio Therapeutics (XLO) Price & Analysis

218 Followers

XLO Stock Chart & Stats

$0.59

-$0.02(-1.59%)

At close: Jan 08 4:00 PM EST

$0.59

-$0.02(-1.59%)

Day’s Range― - ―

52-Week Range$6.46 - $12.74

Previous CloseN/A

Volume162.24K

Average Volume (3M)37.67K

Market Cap

$59.83M

Enterprise Value-$86.16M

Total Cash (Recent Filing)$150.33M

Total Debt (Recent Filing)$6.64M

Price to Earnings (P/E)―

Beta0.31

Next Earnings

Aug 12, 2026

EPS Estimate

-0.59

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.50

Shares Outstanding6,575,139

10 Day Avg. Volume52,834

30 Day Avg. Volume37,670

Financial Highlights & Ratios

PEG Ratio0.03

Price to Book (P/B)21.23

Price to Sales (P/S)17.11

P/FCF Ratio-135.93

Enterprise Value/Market Cap-1.44

Enterprise Value/Revenue-1.61

Enterprise Value/Gross Profit-2.28

Enterprise Value/Ebitda2.88

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)-2.39

Revenue Forecast (FY)$27.31M

Bulls Say, Bears Say

Bulls Say

Clinical DevelopmentManagement aims to partner with other companies to advance the clinical development of vilastobart, showing a proactive approach in expanding potential market reach.

Financial StabilityThe company ended the quarter with $121.6M in cash and cash equivalents, which should sustain operations into 3Q26.

InnovationXilio is on track with strategic nominations for developing targeted therapies, reflecting a clear pipeline and focus on innovation.

Bears Say

Financial PerformanceXilio reported a net loss of $16.3 million, indicating financial challenges that need to be addressed.

Strategic PartnershipsFinding the right partner quickly is critical for both the asset and the company.

Xilio Therapeutics News

Xilio Therapeutics appoints Ben Harshbarger as chief legal officer

Xilio Therapeutics (XLO) announced the appointment of Ben Harshbarger as chief legal officer. recently, he served as chief...

14d ago

XLO

Xilio Therapeutics Adjusts Board Structure Following Shareholder Votes

Xilio Therapeutics ( ($XLO) ) just unveiled an announcement. At its annual meeting on June 10, 2026, Xilio...

1M ago

XLO

Xilio Therapeutics files $250M mixed securities shelf

07:50 EDT Xilio Therapeutics (XLO) files $250M mixed securities shelf Published first on TheFly – the ultimate source...

2M ago

XLO

Xilio announces new preclinical data for XTX601 at AACR

Xilio Therapeutics (XLO) announced new preclinical data for XTX601, a masked T cell engager targeting claudin 18.2, at...

3M ago

XLO

Xilio Therapeutics Announces Board Changes and Committee Leadership

Xilio Therapeutics ( ($XLO) ) has provided an update. On April 15, 2026, Xilio Therapeutics appointed Cheryl R....

3M ago

XLO

Xilio Therapeutics appoints Blanchard to its Board of Directors

Xilio Therapeutics (XLO) announced the appointment of Cheryl Blanchard, Ph.D. to the company’s board of directors. The company...

3M ago

XLO

Upcoming Stock Splits This Week (March 16–20, 2026) – Stay Invested

These are the upcoming stock splits for the week of March 16 to March 20, based on TipRanks’ Stock...

4M ago

XLO

CLIR

Xilio Therapeutics Inc trading halted, news pending

19:50 EDT Xilio Therapeutics (XLO) Inc trading halted, news pending Published first on TheFly – the ultimate source...

4M ago

XLO

Xilio Therapeutics Announces 1-for-14 Reverse Stock Split

Xilio Therapeutics ( ($XLO) ) has issued an update. On March 12, 2026, Xilio Therapeutics announced that it...

4M ago

XLO

Xilio Therapeutics announces 1-for-14 reverse stock split

Xilio Therapeutics (XLO) announced that it will implement a 1-for-14 reverse stock split of the issued shares of...

4M ago

XLO

Xilio Therapeutics Updates Investor Presentation on I-O Strategy

Xilio Therapeutics ( ($XLO) ) has provided an update. On March 9, 2026, Xilio Therapeutics posted an updated...

4M ago

XLO

Xilio Therapeutics announces inducement grants

Xilio Therapeutics (XLO) announced that, effective March 1, 2026, the company granted non-qualified stock options to purchase 50,050...

4M ago

XLO

XLO Earnings Report this Week: Is It a Buy, Ahead of Earnings?

Xilio Therapeutics Inc (XLO) is scheduled to report 4th quarter earnings on 03/04/2026. Regarding Q4 estimates, Wall Street...

4M ago

XLO

Xilio Therapeutics Shareholders Approve Flexible Reverse Stock Split

The latest update is out from Xilio Therapeutics ( ($XLO) ). On February 23, 2026, Xilio Therapeutics, Inc....

5M ago

XLO

XLO FAQ

What was Xilio Therapeutics Inc’s price range in the past 12 months?

Xilio Therapeutics Inc lowest stock price was $6.46 and its highest was $12.73 in the past 12 months.

What is Xilio Therapeutics Inc’s market cap?

Xilio Therapeutics Inc’s market cap is $59.83M.

When is Xilio Therapeutics Inc’s upcoming earnings report date?

Xilio Therapeutics Inc’s upcoming earnings report date is Aug 12, 2026 which is in 30 days.

How were Xilio Therapeutics Inc’s earnings last quarter?

Xilio Therapeutics Inc released its earnings results on May 12, 2026. The company reported -$0.58 earnings per share for the quarter, beating the consensus estimate of -$0.66 by $0.08.

Is Xilio Therapeutics Inc overvalued?

According to Wall Street analysts Xilio Therapeutics Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Xilio Therapeutics Inc pay dividends?

Xilio Therapeutics Inc does not currently pay dividends.

What is Xilio Therapeutics Inc’s EPS estimate?

Xilio Therapeutics Inc’s EPS estimate is -0.59.

How many shares outstanding does Xilio Therapeutics Inc have?

Xilio Therapeutics Inc has 6,575,139 shares outstanding.

What happened to Xilio Therapeutics Inc’s price movement after its last earnings report?

Xilio Therapeutics Inc reported an EPS of -$0.58 in its last earnings report, beating expectations of -$0.66. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Xilio Therapeutics Inc?

Currently, no hedge funds are holding shares in XLO

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Xilio Therapeutics Stock Smart Score

Underperform

Fundamentals

Return on Equity

-117.24%

Trailing 12-Months

Asset Growth

57.63%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Xilio Therapeutics Inc

Xilio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to crafting immunotherapies aimed at strengthening the immune systems of cancer patients. A key part of their pipeline is XTX101, a tumor-selective anti-CTLA-4 monoclonal antibody that is currently undergoing Phase 1/2 clinical trials for various solid tumors. The company also develops a range of cytokine programs, including XTX202 (a modified IL-2), XTX301 (an IL-12 product candidate), and XTX401 (an IL-15 product candidate). These cytokine therapies are ingeniously engineered with a protein domain that keeps them inactive until proteases specific to the tumor microenvironment (TME) cleave this mask, thereby initiating their therapeutic activity. Xilio Therapeutics, Inc. was founded in 2016 and is based in Waltham, Massachusetts.